Bbe Corporation

Cell Signaling Technologies, based in Beverly, MA, is recognized globally for its extensive range of high-quality antibodies and related research products, serving the life sciences community for over 25 years. The company's product offerings include primary and secondary antibodies, ELISA kits, cellular assay kits, and an array of reagents and comprehensive solutions tailored for various applications including cancer research, immunology, and neuroscience. With a commitment to reliability and validation, Cell Signaling Technologies provides leading-edge solutions for research through robust assay platforms and continuous supply of essential products. Their dedication to environmental and social responsibility further underscores their role as a trusted partner in advancing scientific discovery. Generated from the website

With over 40 years of experience, Cotton Brothers Corporation is one of the top worldwide manufacturers and service providers of process piping modules for the biotechnology and pharmaceutical industries. Based in Danvers, Mass., the firm has expertise in bioreactors, fermentation, transfer panel, utility stations, centrifuge, chromatography, pilot system, research and development (R&D) units and others. The company offers engineering services, such as project management, project estimating, custom valve porting, third party inspection services, to name a few. It also specializes in weld repair, vessel repair, mechanical finishing and electro polishing. Cotter Brothers Corporation also provides control systems design, wiring, automation and software engineering process to meet individual needs.

Stoke Therapeutics, Inc., based in Bedford, MA, is pioneering RNA medicine with its proprietary platform, Targeted Augmentation of Nuclear Gene Output (TANGO), aimed at restoring protein expression in diseases caused by gene mutations. The company's focus is primarily on conditions characterized by haploinsufficiencies, including Dravet syndrome and autosomal dominant optic atrophy (ADOA). Stoke's mission is to develop innovative therapies that address the genetic underpinnings of severe diseases, exemplified by their ongoing clinical studies of zorevunersen (STK-001) for Dravet syndrome. Through their commitment to scientific advancement, they aim to improve the lives of patients living with challenges associated with genetic disorders. Generated from the website